Announced today that the U.S. Food & Drug Administration has granted the Company’s Type C meeting request ...
TORONTO, July 25, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty...
FDA accepts Company’s Data Access Plan to determine potential new clinical endpoints to support Emergency Use Authorization...
The Company submits Data Access Plan to the FDA to determine potential new clinical endpoints to support Emergency Use Authorization...
Provides an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial to evaluate ...
The Company received positive comments from the FDA to determine potential new clinical endpoints to support Emergency Use Authorization TORONTO, May 26,...
Provides an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial to evaluate ...
The Company submitted request to the FDA to determine potential new clinical endpoints for FDA consideration for EUA...
TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty...
Announced the publication of a scientific article evaluating the impact of medication, including Bucillamine, ...